Writer on biotechnology and the economics of drug development, with a background working in and around the pharmaceutical industry. He writes long, sourced essays at atelfo.github.io on why drugs are hard to discover, what regulation does to that, and where the industry is going.
Alex Telford did not write this page.
We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording.
Their own site.
Is this you? Claim it or ask us to remove it.Or tell us what is wrong here.
Alex TelfordWriter on biotechnology and the economics of drug developmentAnother challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.↗A new breed of biotechatelfo.github.io · 17 Sept 2024All korrents from this piece
Their wordsAnother challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.
Their wordsThe most significant factor preventing us from taking better molecules into clinical trials is not our ability to design arbitrary molecules, but our (lack of) understanding of underlying disease biology. In other words, we often know how to make something, but not what to make.
Their wordsBecause patents have fixed term lengths, with small extensions to compensate for the year or so when the drug is under regulatory review, drug developers are incentivized to go after conditions where clinical trials can be completed quickly, all else being equal.